Click here : AFPT Newsletter 5_230127
About HENRI CAPLAIN
This author has not written his bio yet.
But we are proud to say that HENRI CAPLAIN contributed 27 entries already.
Entries by HENRI CAPLAIN
If your are interesting to sponsor or to have an exhibition at the next EUFEMED conference in BErlin, please click on the following link : https://ogy.de/EUFEMED-Partnership
If you are interested to submit an abstract, please click on the following link: https://eufemed-conference.eu/2023/wp-content/uploads/Abstract_submision_template_EUFEMED2023.pdf
Programme AFPT_Juin 2022_Final_V5_HC Please click on the following links to see the available presentations (authorised by the Authors): 1_1_Breathing New Life into FTiH Dose Predictions – Inhaled PBPK Modelling – Simon Teague Le Club Phase1 June 2022 1_2_AFPT2022_Balazki 1_3_AFPT_KLH model_JUN2022_extract 1_4_FINAL_AFPT_June 2022_DILIsym CGRP Rc antagonists 2_1_Massard BASKET P1 AFPT2022vfinal 2_2_AFPT_ master protocol _16June2022_MH 2_3_French Club […]
7 October 2022 – ONLINE
02 March 2022, 17:00 – 02 March 2022, 18:30 (UTC+01:00) Bruxelles, Copenhague, Madrid, Paris REGISTRATION LINK (MANDATORY): https://teams.microsoft.com/registration/tgoS-U_pR0GIPMJJajtO5Q,iiwcKel7s0Wn59cprzvTGg,yx6hQ9XN9Eq3n0HmXyIXWQ,ED2KZGrLSEeMoEMg0wARoA,Qtdma1XV_UyYXI6cScx66A,jxHTtmIYkkKap-g2HEEe6Q?mode=read&tenantId=f9120ab6-e94f-4147-883c-c2496a3b4ee5
Programme AFPT_Juin 2022_Final_V2_HC
Job offer: Crossject – CDI Chef(fe) de projet étude clinique Click on the following link for the job description: CDI Chef de projet étude clinique
Job offer: Medical Director – Clinical Pharmacology (Neuroscience) | Novartis
Conference_Eufemed_2021 Programme click on: https://www.eufemed-conference.eu/2021/programme/
AFPT-Club Phase 1
French association of the professionals of human and translational pharmacology
34, avenue des Champs-Elysées 75008 Paris 8ème, France
A founding member of
EUROPEAN FEDERATION FOR EXPLORATORY MEDICINES DEVELOPMENT
After the two first successful sessions, the AFPT-CP1 will run the third session of its pre-clinical and clinical safety in early development human trial course in cooperation with EUFEMED, its
After the two first successful sessions, the AFPT-CP1 will run the third session of its pre-clinical and clinical safety in early development human trial course in cooperation with EUFEMED, its European Federation, and Paris-Saclay University.
If you are interested by the programme, you please register:
Registration deadline: 05 March 2024
This training course will take place from 18-22nd of March 2024 in Saclay in the south of Paris (onsite).
It is a 5-day course on ‘Pre-Clinical and Clinical Safety in Early Development Human Trials’ recognized by Paris-Saclay University and EUFEMED, forming part of a diploma.
It follows the European ‘Pharmatrain’ syllabus, and a certification will be requested in the next future.
It is held in English and is intended for people working in the pharmaceutical industry and students who would like to know more on this sensitive topic.
Do not hesitate to speak of this advanced training to you colleagues who could be interested”
Course exclusively in English and in presential due to its interactive nature.
Minimal number of participants: 10
18 (Monday) 9 h 00 min - 22 (Friday) 16 h 00 min ECT
Site Henri Moissan Université Paris-Saclay
17 avenue des Sciences
AFPT - Le Club Phase 1